Trial Profile
A biomarker analysis of Afatinib treatment in patients with relapse of EGFR-T790M mutation-positive advanced lung adenocarcinoma after 3rd generation EGFR-TKI treatment.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2016
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 06 Dec 2016 New trial record